Market closedNon-fractional
Xenon Pharmaceuticals/XENE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
Ticker
XENE
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Burnaby, Canada
Employees
255
Website
www.xenon-pharma.com
XENE Metrics
BasicAdvanced
$3.3B
Market cap
-
P/E ratio
-$2.70
EPS
1.22
Beta
-
Dividend rate
Price and volume
Market cap
$3.3B
Beta
1.22
Financial strength
Current ratio
31.823
Quick ratio
31.518
Long term debt to equity
1.025
Total debt to equity
1.174
Management effectiveness
Return on assets (TTM)
-17.09%
Return on equity (TTM)
-23.95%
Valuation
Price to book
3.75
Price to tangible book (TTM)
3.75
Price to free cash flow (TTM)
-19.425
Growth
Earnings per share change (TTM)
15.22%
3-year earnings per share growth (CAGR)
45.08%
What the Analysts think about XENE
Analyst Ratings
Majority rating from 17 analysts.
XENE Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$48M
7.16%
Profit margin
0.00%
NaN%
XENE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.72
-$0.73
-$0.64
-$0.62
-
Expected
-$0.70
-$0.77
-$0.76
-$0.66
-$0.70
Surprise
3.25%
-5.70%
-15.70%
-6.66%
-
XENE News
AllArticlesVideos
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewsWire·2 months ago
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
GlobeNewsWire·2 months ago
Polarean Imaging lands new hospital order for Xenon MRI System
Proactive Investors·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xenon Pharmaceuticals stock?
Xenon Pharmaceuticals (XENE) has a market cap of $3.3B as of July 27, 2024.
What is the P/E ratio for Xenon Pharmaceuticals stock?
The price to earnings (P/E) ratio for Xenon Pharmaceuticals (XENE) stock is 0 as of July 27, 2024.
Does Xenon Pharmaceuticals stock pay dividends?
No, Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Xenon Pharmaceuticals dividend payment date?
Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders.
What is the beta indicator for Xenon Pharmaceuticals?
Xenon Pharmaceuticals (XENE) has a beta rating of 1.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Xenon Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.